Given that prophylactic LDA may be associated with an increased risk of intracranial haemorrhage in healthy subjects [73], the question of whether all SLE patients with a low-risk aPL profile and no history of clinical thrombosis should receive a LDA is controversial. The gene discussed is FASLG; the disease is systemic lupus erythematosus.